AHA 2005

NSAIDs Raise Death Risk post-MI

Gunnar Gislason
Gunnar Gislason

As the dust continues to settle on the Vioxx issue, there is naturally a desire to look further at potential cardiovascular risks associated with COX-2 inhibitors and, indeed, other non-steroidal anti-inflammatories. Gunnar Gislason from Bispebjerg University Hospital has been leading a study aiming to look throughout Denmark for a relationship between the use of these drugs and mortality in people who have had a myocardial infarction.

Click here for all the interviews from AHA 2005

Similar Interviews

  • Pexelizumab Reduces Mortality in High Risk Coronary Artery By-Pass Patients
  • Peter Smith, Duke University Medical Center, Durham, NC Late Breaking Clinical Trials, ACC Atlanta 2006, Sunday 12th March 2006 The drug pexelizumab,

  • Statins and ARBs: a Special Combination?
  • John McMurray The VALIANT trial compared ACE-inhibitor, ARB and a combination of the two in high-risk post-MI patients, and found

  • Diabetic Patients: Some Benefits from Fibrates
  • Anthony Keech Among nearly 10 000 patients with maturity onset diabetes the use of fenofibrate to lower cholesterol produced a 24

    Post a comment

    Subscribe to Audio Medica Podcast